Improvement in nail psoriasis severity at 16 weeks versus placebo; maintained through 52 weeks
TUESDAY, June 20, 2017 (HealthDay News) — Tofacitinib is associated with improvements in nail psoriasis, according to a study published in the July issue of the Journal of the American Academy of Dermatology.
Joseph F. Merola, M.D., from Brigham and Women’s Hospital in Boston, and colleagues examined the efficacy of tofacitinib for nail psoriasis treatment over 52 weeks in two identical phase 3 studies. Patients were randomized to receive tofacitinib 5 mg (487 patients), tofacitinib 10 mg (476 patients), or placebo (233 patients) twice daily. Placebo-treated patients were re-randomized at week 16.
The researchers found that significantly more patients receiving tofacitinib 5 mg and tofacitinib 10 mg versus placebo achieved a ≥50 percent reduction in the Nail Psoriasis Severity Index (NAPSI) score from baseline (NAPSI50) (32.8 and 44.2, respectively, versus 12.0 percent), NAPSI75 (16.9 and 28.1, respectively, versus 6.8 percent), and NAPSI100 (10.3 and 18.2, respectively, versus 5.1 percent) at week 16. The improvements were maintained to week 52.
“Tofacitinib treatment resulted in improvements in nail psoriasis versus placebo at week 16; improvements were maintained over 52 weeks,” the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Pfizer, which manufactures tofacitinib and funded the study.
Copyright © 2017 HealthDay. All rights reserved.
